Invaio Sciences raises $25M Series C for bioelectronic crop protection platform
Summary
Cambridge-based Invaio Sciences secured $25M Series C from Flagship Pioneering and Leaps by Bayer to scale their bioelectronic plant health platform. Their low-power electrical stimulation delivered through plant stems triggers systemic acquired resistance, reducing fungal and bacterial crop losses without chemical pesticides. Field trials across 10,000 acres show 35% reduction in losses.
Why it matters
Bioelectronic agriculture is an emerging neurotech-adjacent application that applies neural-interface thinking to plant physiology. Invaio's 35% crop loss reduction across 10,000 acres is commercially compelling. Bayer's investment signals the largest agrochemical company is hedging toward bioelectronic alternatives to their own pesticide business.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial